# A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

> **NCT06465186** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 80 (estimated)

## Conditions studied

- Non-alcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
- NAFLD
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Metabolic Dysfunction-associated Steatohepatitis

## Interventions

- **COMBINATION_PRODUCT:** Efinopegdutide
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT06465186
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-12
- **Primary completion:** 2026-08-06
- **Final completion:** 2026-08-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465186, "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06465186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*